Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

181.

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.

Lancet.
Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL.
| Aug 17, 2013
182.

Adult obstructive sleep apnoea.

Lancet.
Jordan AS, McSharry DG, Malhotra A.
| Feb 22, 2014
183.

WHO's new HIV guidelines: opportunities and challenges.

Lancet.
Mayer K, Beyrer C.
| Jul 27, 2013
184.

Karyomegalic interstitial nephritis.

Lancet.
Zschiedrich S, Huber TB, Hildebrandt F, Mihatsch MJ, Wiech T.
| Dec 21, 2013
185.

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Lancet.
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ.
| Jul 6, 2013
186.

First-line treatment of indolent lymphoma: axing CHOP?

Lancet.
Jacobson CA, Freedman AS.
| Apr 6, 2013
187.

Metchnikoff and the microbiome.

Lancet.
Podolsky SH.
| Nov 24, 2012
188.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Lancet.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, Samonigg H.
| Jan 26, 2013
189.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Lancet.
Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS.
| Dec 8, 2012
190.

Ventricular arrhythmias and sudden cardiac death.

Lancet.
John RM, Tedrow UB, Koplan BA, Albert CM, Epstein LM, Sweeney MO, Miller AL, Michaud GF, Stevenson WG.
| Oct 27, 2012
191.

Postoperative radiation for prostate cancer.

Lancet.
Efstathiou JA.
| Dec 8, 2012
192.

Health-care reforms in the USA and England: areas for useful learning.

Lancet.
Blumenthal D, Dixon J.
| Oct 13, 2012
193.

EXAMINATION of new drug-eluting stents--top of the class!

Lancet.
Bhatt DL.
| Oct 27, 2012
194.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Lancet.
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Zucchiatti N.
| Oct 20, 2012
195.

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Lancet.
Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA.
| Oct 13, 2012
196.

How much CABG is good for us?

Lancet.
Jones DS.
| Aug 11, 2012
197.

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Lancet.
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.
| Aug 11, 2012
199.

Comprehensive clinical care for men who have sex with men: an integrated approach.

Lancet.
Mayer KH, Bekker LG, Stall R, Grulich AE, Colfax G, Lama JR.
| Jul 28, 2012
200.

Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy.

Lancet.
Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Alkandari JR.
| Jul 21, 2012